| Project/Area Number |
25640067
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor biology
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KONDO Shinji 大学共同利用機関法人情報, システム研究機構(新領域融合研究センター), 特任准教授 (30415161)
KATO Hidemasa 埼玉医科大学, 医学部, 講師 (50292123)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 薬剤耐性 / 非コードRNA / エピジェネティクス / トランスクリプトーム / RNA-seq / アンチセンスRNA |
|---|
| Outline of Final Research Achievements |
We established a drug-resistant cell line DTP (non-proliferative immediately after drug treatment), DTEP (cell proliferation resumed), DTEP-r (drug-sensitive after a long culture without drug), starting with PC9 cells, derived from human non-small cell lung cancer, using anticancer drug, gefitinib. We performed RNA-seq (mRNA and total RNA) for each cell line, and identified ncRNA producing gene loci showing unique expression balances between poly(A)+RNA and total RNA. We also obtained differential expression profiles of several genes among cell types, which suggested the phenotypic differences among cell types were due to epigenetic changes.
|
